Jeffrey Jones’ Post

Grail, a company specializing in liquid biopsy for cancer detection, is set to debut on Nasdaq amid significant challenges. CEO Bob Ragusa believes their test, Galleri, will revolutionize cancer screening when integrated into standard care. Grail's journey includes being spun out from Illumina in 2015, a failed acquisition by Illumina in 2020 due to regulatory hurdles, and subsequent re-emergence. Despite annual losses of approximately $500 million, Grail plans to seek full U.S. approval for Galleri by 2026, funded for the near future by Illumina. Click here to read more: https://bit.ly/3KWrWBZ #liquidbiopsy #nextgenerationsequencing #nasdaq #venturecapital #privateequity #deerbornedifference

🌟 Avacta Therapeutics Partners with Tempus AI to Advance Precision Oncology! 🌟 Avacta Therapeutics and Tempus AI have teamed up to drive the development of FAP-based Peptide Drug Conjugates using Tempus' expansive clinical datasets. Avacta will leverage real-world data from 200,000+ tumor samples to better target solid tumors using its PreCision platform. 🎯 With Tempus' analytical expertise, the goal is smarter clinical development, fast-tracking innovative therapies for cancer patients. 💥 Exciting strides in precision medicine! 🚀 #Oncology #PrecisionMedicine #DrugDevelopment #AIinHealthcare #FAPTargeting #Avacta #TempusAI #Biotech #CancerResearch

TSO500 DNA and RNA methods now available on Beckman NGeniuS. Easy to use, small footprint, low hands-on time, affordable automation

📰 🎙️ In an exclusive Q&A with Drug Target Review, our CEO Dr. Alan D. Roth discusses how Oxford Drug Design achieved the first in vivo validation for a potential first-in-class cancer treatment. Our 28-day mouse trial demonstrated clear efficacy and dose response, made possible by our dual-competency discovery platform, which combines generative AI with deep expertise in tRNA synthetases. Alan delves into the trial results, how this breakthrough could transform therapeutic options for multiple tumours, and the role of our cutting-edge AI platform, SynthAI, in revolutionising drug discovery. Read the full interview here 👉 https://lnkd.in/eGsBDNZA #AI #drugdiscovery #cancerresearch #biotech #pharmaceuticalindustry

Join this Webinar happening now to learn about all the latest in Precision Medicine!

Join Predicine at the 8th Annual Liquid Biopsy For Precision Oncology Summit in San Diego from Feb. 28 to March 1st! Come and visit us at Predicine booth #15 and discover how we transform the MRD space through tumor-informed and tumor-naive liquid biopsy technology.     At the conference, our Founder and CEO Shidong Jia will take the stage and reveal our innovative oncology liquid biopsy testing in global clinical trials & CDx development.    Highlights:    • LBx technology innovation in ctDNA and cfRNA, Breakthrough Device Designation granted by FDA   • Blood/urine/tissue-based NGS solution, including mutation and methylation-based MRD detection   • Global clinical trial and CDx development in the US, China, and the ROW   Schedule a meeting with the Predicine team: https://lnkd.in/g8JK7vuc     Learn more about Predicine: https://lnkd.in/gndzmpGH     #diagnostics #oncology #NGS #liquidbiopsy #MRD #ctDNA #CDx

What needs to happen for #NGS to become a truly disruptive technology? . Join us as we discuss the future of precision oncology and the potential of unlocking greater scale and patient access to next generation cancer care. #precisiononcology #precisionmedicine #cancercare

Can’t wait for more insights from upcoming papers. Looking ahead, this research aims to advance immune checkpoint inhibitor therapies and fine-tune T-cell responses against solid tumors. Go Team ATCC!!

💫In case you missed it - #SOHO2024 poster is now up! Last week, we presented at the Society of Hematologic Oncology 2024 annual meeting. Our scientist Jianli Zhou, Ph.D., shared some of the innovative work powered by Lantern Pharma Inc. (Nasdaq: LTRN)'s AI platform RADR® and were able to connect with the #CancerResearch community. Leveraging Artificial Intelligence, Machine Learning, and genomics, we are working towards transforming the cost, pace, and timeline of oncology drug discovery and development. In our poster presented at #SOHO, we highlighted updates on our drug candidate LP-284, currently in Phase 1 #clinicaltrial for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas and Solid Tumors. Check out the poster at our website: https://bit.ly/3yIRBLW #Oncology #OncologyResearch #2024SOHO

Struggling because you don't have the right licenses for your research cell lines? We offer the largest selection of fully licensed cell lines to propel your research with peace of mind. With industry-leading coverage of cell line IP utilization, here's what sets us apart: ✅~900 Commercially Licensed Cell Lines: Access an unparalleled variety of cell lines across multiple cancer indications. ✅Easy Material Transfer Process: Streamlining the acquisition of commercial cell lines to save you time and hassle. ✅Simple Solutions for Non-licensable Cell Lines: Navigate through licensing hurdles with ease and focus on what truly matters - your research. Don't let licensing limits hold you back. Get started ➡️ https://bit.ly/3Vt26vz #CellLines #CancerResearch #Bioscience